GSK Stockmann has added Arne Bolch to the firm’s Luxembourg team of partners alongside Dr Marcus Peter, Andreas Heinzmann, Dr Philipp Mössner and Mathilde Ostertag, as a new local partner.
Arne Bolch has been working in Luxembourg for more than 11 years in the Luxembourg office of Allen & Overy and more recently at Clifford Chance as counsel. His main areas of expertise include fund formation advice for alternative investment funds (AIF) as well as traditional retail (UCITS) funds. He also assists clients in fund related M&A transactions and general investment fund and regulatory law matters. In the past, Arne advised initiators and (in particular German) institutional investors in their dealings with Luxembourg investment funds. Previous deals include advising LoneStar on its sale of the real-estate portfolio, previously owned by Deutsche Post to a Canadian REIT, as well as Patrizia Immobilien AG on their LBBW and GBW transactions. At Clifford Chance, he was part of the team that helped set up the first RAIF in the form of a common fund (FCP) under Luxembourg law.
“We are delighted to add Arne Bolch to our team. Arne is very experienced in the field of investment fund and regulatory law. His deep knowledge of Luxembourg investment structures will benefit our international client base in particular in relation to cross-border fund transactions,” says Dr Marcus Peter, partner and head of the private equity and funds practice at GSK Luxembourg.
Robert Kramer, head of the practice group banking/finance at GSK Stockmann, adds: “Arne’s expertise as well as experience in investment and regulatory law, in particular, in derivatives and MiFiD II, perfectly complements our investment fund and regulatory practices here in Germany. This will further enhance our capabilities to provide seamless advice out of our German and Luxembourg offices.”
The team at GSK Stockmann in Luxembourg with Arne now grows to over 20 lawyers.
